Nasal gene expression changes with inhaled corticosteroid treatment in asthma

Ilse M Boudewijn; Andy Lan; Alen Faiz; Claire A Cox; Sharon Brouwer; Siebrig Schokker; Sebastiaan J Vroegop; Martijn C Nawijn; Prescott G Woodruff; Stephanie A Christenson; Paul Hagedoorn; Henderik W Frijlink; David F Choy; Uilke Brouwer; Marissa Wisman; Dirkje S Postma; James Fingleton; Richard Beasley; Maarten van den Berge; Victor Guryev

doi:10.1111/all.13952

Nasal gene expression changes with inhaled corticosteroid treatment in asthma

Ilse M Boudewijn^*, Andy Lan, Alen Faiz, Claire A Cox, Sharon Brouwer, Siebrig Schokker, Sebastiaan J Vroegop, Martijn C Nawijn, Prescott G Woodruff, Stephanie A Christenson, Paul Hagedoorn, Henderik W Frijlink, David F Choy, Uilke Brouwer, Marissa Wisman, Dirkje S Postma, James Fingleton, Richard Beasley, Maarten van den Berge, Victor Guryev

^*Bijbehorende auteur voor dit werk

Onderzoeksoutput › Academic › peer review

2 Citaten (Scopus)

142 Downloads (Pure)

Originele taal-2	English
Pagina's (van-tot)	191-194
Aantal pagina's	4
Tijdschrift	Allergy
Volume	75
Nummer van het tijdschrift	1
Vroegere onlinedatum	22-jun.-2019
DOI's	https://doi.org/10.1111/all.13952
Status	Published - 1-jan.-2020

Toegang tot document

10.1111/all.13952

Nasal gene expression changes with inhaled corticosteroid treatment in asthmaFinal author's version, 295 KBLicentie: Unspecified

Handle.net

Permanente koppeling

Document onder embargo

Nasal gene expression changes with inhaled corticosteroid treatment in asthma
Final publisher's version, 648 KB
Kopie aanvragen

Citeer dit

Boudewijn, I. M., Lan, A., Faiz, A., Cox, C. A., Brouwer, S., Schokker, S., Vroegop, S. J., Nawijn, M. C., Woodruff, P. G., Christenson, S. A., Hagedoorn, P., Frijlink, H. W., Choy, D. F., Brouwer, U., Wisman, M., Postma, D. S., Fingleton, J., Beasley, R., van den Berge, M., & Guryev, V. (2020). Nasal gene expression changes with inhaled corticosteroid treatment in asthma. Allergy, 75(1), 191-194. https://doi.org/10.1111/all.13952

@article{6dcd3288d9a2405e9875a47eaf1047ef,

title = "Nasal gene expression changes with inhaled corticosteroid treatment in asthma",

author = "Boudewijn, {Ilse M} and Andy Lan and Alen Faiz and Cox, {Claire A} and Sharon Brouwer and Siebrig Schokker and Vroegop, {Sebastiaan J} and Nawijn, {Martijn C} and Woodruff, {Prescott G} and Christenson, {Stephanie A} and Paul Hagedoorn and Frijlink, {Henderik W} and Choy, {David F} and Uilke Brouwer and Marissa Wisman and Postma, {Dirkje S} and James Fingleton and Richard Beasley and {van den Berge}, Maarten and Victor Guryev",

note = "Funding Information: The OLiVIA study was funded by TEVA pharmaceutical Industries Ltd. The NZRHS study was funded by the Health Research Council of New Zealand (grant no 10/174), Astra Zeneca Ltd and Genentech. MvdB reports grants paid to the University from Astra Zeneca, TEVA, GSK, and Chiesi. IMB reports consultancy fees paid to the University from GSK. MCN reports grants paid to the University from GSK. PGW reports a grant from Medimmune and consultancy fees from Astra Zeneca, Regeneron, Sanofi, Genentech, Novartis, and Glemmark. SAC reports a grant from Medimmune, fees from Astra Zeneca and nonfinancial support from Genentech. PH is involved in development and design of the Twincer high-dose dry powder inhaler, and his employer receives royalties from the sales of the Novolizer and Genuair. HWF has a patent WO2003/000325 with royalties paid to Astra-Zeneca and his employer receives royalties from the sales of Genuair products. DFC is an employee of Genentech and has submitted patents for methods for the diagnosis and treatment of respiratory disease patients. DSP reports grants paid to the University from Astra Zeneca, Chiesi, Genentech, GSK, and Roche and reports consultancy fees paid to the University by Astra Zeneca, Chiesi, and GSK. JF reports grants from Health Research Council of New Zealand, AstraZeneca, GSK, Fisher & Paykel, and Genentech; fees from AstraZeneca and Boehringer-Ingelheim and nonfinancial support from Novartis and Boehringer-Ingelheim. RB reports grants from Health Research Council of New Zealand, Astra Zeneca, GSK, and Genentech and fees from Astra Zeneca. AL, AF, CAC, SB, SS, SJV, UB, MW, and VG have nothing to disclose.",

year = "2020",

month = jan,

day = "1",

doi = "10.1111/all.13952",

language = "English",

volume = "75",

pages = "191--194",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "1",

}

Boudewijn, IM, Lan, A, Faiz, A, Cox, CA, Brouwer, S, Schokker, S, Vroegop, SJ, Nawijn, MC, Woodruff, PG, Christenson, SA, Hagedoorn, P , Frijlink, HW, Choy, DF, Brouwer, U , Wisman, M, Postma, DS, Fingleton, J, Beasley, R, van den Berge, M & Guryev, V 2020, 'Nasal gene expression changes with inhaled corticosteroid treatment in asthma', Allergy, vol. 75, nr. 1, blz. 191-194. https://doi.org/10.1111/all.13952

TY - JOUR

T1 - Nasal gene expression changes with inhaled corticosteroid treatment in asthma

AU - Boudewijn, Ilse M

AU - Lan, Andy

AU - Faiz, Alen

AU - Cox, Claire A

AU - Brouwer, Sharon

AU - Schokker, Siebrig

AU - Vroegop, Sebastiaan J

AU - Nawijn, Martijn C

AU - Woodruff, Prescott G

AU - Christenson, Stephanie A

AU - Hagedoorn, Paul

AU - Frijlink, Henderik W

AU - Choy, David F

AU - Brouwer, Uilke

AU - Wisman, Marissa

AU - Postma, Dirkje S

AU - Fingleton, James

AU - Beasley, Richard

AU - van den Berge, Maarten

AU - Guryev, Victor

N1 - Funding Information: The OLiVIA study was funded by TEVA pharmaceutical Industries Ltd. The NZRHS study was funded by the Health Research Council of New Zealand (grant no 10/174), Astra Zeneca Ltd and Genentech. MvdB reports grants paid to the University from Astra Zeneca, TEVA, GSK, and Chiesi. IMB reports consultancy fees paid to the University from GSK. MCN reports grants paid to the University from GSK. PGW reports a grant from Medimmune and consultancy fees from Astra Zeneca, Regeneron, Sanofi, Genentech, Novartis, and Glemmark. SAC reports a grant from Medimmune, fees from Astra Zeneca and nonfinancial support from Genentech. PH is involved in development and design of the Twincer high-dose dry powder inhaler, and his employer receives royalties from the sales of the Novolizer and Genuair. HWF has a patent WO2003/000325 with royalties paid to Astra-Zeneca and his employer receives royalties from the sales of Genuair products. DFC is an employee of Genentech and has submitted patents for methods for the diagnosis and treatment of respiratory disease patients. DSP reports grants paid to the University from Astra Zeneca, Chiesi, Genentech, GSK, and Roche and reports consultancy fees paid to the University by Astra Zeneca, Chiesi, and GSK. JF reports grants from Health Research Council of New Zealand, AstraZeneca, GSK, Fisher & Paykel, and Genentech; fees from AstraZeneca and Boehringer-Ingelheim and nonfinancial support from Novartis and Boehringer-Ingelheim. RB reports grants from Health Research Council of New Zealand, Astra Zeneca, GSK, and Genentech and fees from Astra Zeneca. AL, AF, CAC, SB, SS, SJV, UB, MW, and VG have nothing to disclose.

PY - 2020/1/1

Y1 - 2020/1/1

U2 - 10.1111/all.13952

DO - 10.1111/all.13952

M3 - Letter

C2 - 31230369

VL - 75

SP - 191

EP - 194

JO - Allergy

JF - Allergy

SN - 0105-4538

IS - 1

ER -